Eli Lilly downgraded by Berenberg with a new price target
$LLY
Biotechnology: Pharmaceutical Preparations
Health Care
Berenberg downgraded Eli Lilly from Buy to Hold and set a new price target of $830.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/20/2025 | $840.00 → $930.00 | Outperform | BMO Capital Markets |
| 10/14/2025 | Hold → Buy | Erste Group | |
| 9/17/2025 | $830.00 | Buy → Hold | Berenberg |
| 8/27/2025 | $700.00 | Reduce → Hold | HSBC Securities |
| 8/18/2025 | $700.00 | Outperform → Neutral | Daiwa Securities |
| 8/7/2025 | $715.00 | Outperform → Market Perform | Leerink Partners |
| 6/5/2025 | Buy → Hold | Erste Group | |
| 4/28/2025 | $1150.00 → $700.00 | Buy → Reduce | HSBC Securities |
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
BMO Capital Markets reiterated coverage of Eli Lilly with a rating of Outperform and set a new price target of $930.00 from $840.00 previously
Erste Group upgraded Eli Lilly from Hold to Buy
Berenberg downgraded Eli Lilly from Buy to Hold and set a new price target of $830.00
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
4 - ELI LILLY & Co (0000059478) (Issuer)
10-Q - ELI LILLY & Co (0000059478) (Filer)
8-K - ELI LILLY & Co (0000059478) (Filer)
8-K - ELI LILLY & Co (0000059478) (Filer)
Revenue in Q3 2025 increased 54% to $17.60 billion driven by volume growth from Mounjaro and Zepbound.Q3 2025 EPS increased by $5.14 to $6.21 on a reported basis and increased by $5.84 to $7.02 on a non-GAAP basis. Increased our 2025 full-year revenue guidance to be in the range of $63.0 billion to $63.5 billion; reported EPS guidance raised to be in the range of $21.80 to $22.50 and non-GAAP EPS guidance raised to be in the range of $23.00 to $23.70. Pipeline progress included positive results in four Phase 3 trials of orforglipron, across type 2 diabetes and obesity, with plans to submit to global regulatory authorities by the end of the year for the treatment of obesity. Regulatory progre
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs INDIANAPOLIS, Oct. 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today a planned investment of more than $1.2 billion to expand and modernize its Lilly del Caribe manufacturing site in Carolina, Puerto Rico. This new investment will integrate advanced technologies and expand production capacity within the existing campus to support the company's growing portfolio of oral solid medicines in cardiometabolic health, neuroscience, oncology and immunology. The enhanced facility will be among those that will manufacture orforglipron, Lilly's first oral, small molecule GLP-1 receptor agonist, whic
NetworkNewsWire Editorial Coverage NEW YORK, Oct. 29, 2025 /PRNewswire/ -- The global cancer-therapy landscape is undergoing a rapid evolution toward precision drug-delivery systems designed to boost efficacy, limit toxicity and elevate patient outcomes. Conventional oral and intravenous treatments continue to face significant challenges, chief among them low bioavailability and inadequate tumor targeting. These factors often limit the success of these treatments in clinical settings. Breakthroughs in nanomedicine are now addressing these obstacles, with growing support from the U.S. Food and Drug Administration (FDA), along with other regulators for nanocarrier-based delivery technologies u
For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa
For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ
For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose Acquisition aligns Lilly's genetic medicine capabilities with opportunity to expand gene therapy's potential to alleviate the burden of age-related diseases INDIANAPOLIS and REDWOOD CITY, Calif., Oct. 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Adverum Biotechnologies, Inc. (NASDAQ:ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy with the aim of preserving sight for life in highly prevalent ocular diseases, today announced a definitive agreement for Lilly to acquire Adve
INDIANAPOLIS, Aug. 20, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that Anne White, executive vice president and president, Lilly Neuroscience, will be retiring from Lilly after 30 years of service, effective Dec. 31, 2025. She will continue to serve in her role and as a member of Lilly's Executive Committee until her retirement date. An internal and external search is underway for her successor."Anne's career has been defined by a deep commitment to advancing medicines for some of the most challenging diseases affecting patients globally," said David A. Ricks, Lilly's chair and CEO. "As leader of Lilly Neuroscience, Anne led the global launch of our first ever Alzh
USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 24, 2025 /PRNewswire/ -- With populations again, and chronic diseases on the rise, global healthcare systems are facing enormous challenges ahead. However, there is hope on the horizon to alleviate some of these burdens, coming from the rise of AI in healthcare, as the new tech is proving it can improve diagnostic accuracies, drug discoveries, and administration work flow. Healthcare leaders are already reporting benefits, including reduced clinician workloads through voice-based AI tools and the use of AI agents to boost efficiency and support smarter care delivery. Behind the scenes, the tech is b
Revenue in Q3 2025 increased 54% to $17.60 billion driven by volume growth from Mounjaro and Zepbound.Q3 2025 EPS increased by $5.14 to $6.21 on a reported basis and increased by $5.84 to $7.02 on a non-GAAP basis. Increased our 2025 full-year revenue guidance to be in the range of $63.0 billion to $63.5 billion; reported EPS guidance raised to be in the range of $21.80 to $22.50 and non-GAAP EPS guidance raised to be in the range of $23.00 to $23.70. Pipeline progress included positive results in four Phase 3 trials of orforglipron, across type 2 diabetes and obesity, with plans to submit to global regulatory authorities by the end of the year for the treatment of obesity. Regulatory progre
INDIANAPOLIS, Oct. 27, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the fourth quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on December 10, 2025, to shareholders of record at the close of business on November 14, 2025. About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new d
INDIANAPOLIS, Oct. 16, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will announce its third-quarter 2025 financial results on October 30, 2025. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call. About LillyLilly is a medicine company turning science into heal
SC 13G/A - ELI LILLY & Co (0000059478) (Subject)
SC 13G/A - ELI LILLY & Co (0000059478) (Subject)
SC 13G/A - ELI LILLY & Co (0000059478) (Subject)